BioSpace News Archive

Takeda Pharmaceutical Company Limited announced that it has been named in the 2019 Dow Jones Sustainability World Index, achieving more than double the average overall industry score.

Chinese Academy of Sciences scientist recognized for his work in medicinal chemistry and drug discovery

The SanBio Group announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) Designation for SB623 cell therapy for the treatment of chronic neurological motor deficits secondary to traumatic brain injury (TBI).

AveXis announced that new interim data from the Phase 3 SPR1NT trial in pre-symptomatic patients as well as interim data from the ongoing Phase 3 STR1VE clinical program for Zolgensma®

Technology enables targeted sequencing for rapid, precise DNA analysis on portable or large sequencers

Innovent Biologics, Inc. announed that the results of efficacy and safety of IBI305 (bevacizumab biosimilar) versus bevacizumab, both in combination with paclitaxel/carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) patients in a randomized, double-blind Phase III clinical trial (CTR20160848), were presented in an oral session at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) [Thursday, September 19, 11:25 AM -11:30 AM BJT].

Presentations include findings on biomarkers in rare, untreatable form of testicular cancer, and analysis of differential responses to BRAF inhibitors in melanoma and colorectal cancers

Provincial reimbursement provides public access to treatment that may delay the progression of advanced breast cancer

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body’s immune system to fight cancer, today announced that Potomac Urology Center, PC (“PUC”) has joined its Cchek™ early cancer detection study.

Management is scheduled to present at 3:30-4:00p ET.